BMT CTN State of the Science Symposium 2021: Looking Forward as the Network Celebrates its 20th Year.

No abstract is available for this paper.

• Publication year

  2021

• Venue

  Transplantation and Cellular Therapy

• Publication date

  2021-08-01

• Fields of study

  Medicine, Political Science

• Identifiers
  DOI 10.1016/j.jtct.2021.08.016PMID 34461278PMCID PMC8556300
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Building a Fit for Purpose Clinical Trials Infrastructure to Accelerate the Assessment of Novel Hematopoietic Cell Transplantation Strategies and Cellular Immunotherapies.

  2021cited by this paper
• Bortezomib, lenalidomide, and dexamethasone with or without elotuzumab in patients with untreated, high-risk multiple myeloma (SWOG-1211): primary analysis of a randomised, phase 2 trial.

  2021cited by this paper
• Clinical characteristics and outcomes of COVID-19 in haematopoietic stem-cell transplantation recipients: an observational cohort study

  2021cited by this paper
• Phase II Trial of Costimulation Blockade With Abatacept for Prevention of Acute GVHD

  2021cited by this paper
• Real-world evidence of tisagenlecleucel for pediatric acute lymphoblastic leukemia and non-Hodgkin lymphoma.

  2020cited by this paper
• Precision medicine treatment in acute myeloid leukemia using prospective genomic profiling: feasibility and preliminary efficacy of the Beat AML Master Trial

  2020cited by this paper
• Association of Measurable Residual Disease With Survival Outcomes in Patients With Acute Myeloid Leukemia: A Systematic Review and Meta-analysis.

  2020cited by this paper
• Reduced immunogenicity of the adjuvanted recombinant zoster vaccine after hematopoietic cell transplant: a pilot study.

  2020cited by this paper
• Quantifying skin stiffness in graft-versus-host disease, morphea and systemic sclerosis using acoustic radiation force impulse imaging and shear wave elastography.

  2020cited by this paper
• 25 years of research put RIPK1 in the clinic.

  2020cited by this paper
• Multidimensional analyses of donor memory-like NK cells reveal new associations with response after adoptive immunotherapy for leukemia.

  2020cited by this paper
• Clinical and radiologic correlates of neurotoxicity after axicabtagene ciloleucel in large B-cell lymphoma.

  2020cited by this paper
• Abatacept is effective as GVHD prophylaxis in unrelated donor stem cell transplantation for children with severe sickle cell disease.

  2020cited by this paper
• International harmonization in performing and reporting minimal residual disease assessment in multiple myeloma trials

  2020cited by this paper
• Clinical efficacy of anakinra to mitigate CAR T-cell therapy-associated toxicity in large B-cell lymphoma.

  2020cited by this paper
• Geriatric assessment-driven intervention (GAIN) on chemotherapy toxicity in older adults with cancer: A randomized controlled trial.

  2020cited by this paper
• Risk score to predict event-free survival after hematopoietic cell transplant for sickle cell disease.

  2020cited by this paper
• Tafasitamab plus lenalidomide in relapsed or refractory diffuse large B-cell lymphoma (L-MIND): a multicentre, prospective, single-arm, phase 2 study.

  2020cited by this paper
• Standard-of-Care Axicabtagene Ciloleucel for Relapsed or Refractory Large B-Cell Lymphoma: Results From the US Lymphoma CAR T Consortium.

  2020cited by this paper
• KTE-X19 CAR T-Cell Therapy in Relapsed or Refractory Mantle-Cell Lymphoma.

  2020cited by this paper
• Facilitating resolution of life-threatening acute GVHD with human chorionic gonadotropin and epidermal growth factor.

  2020cited by this paper
• Feasibility of Centralized Electronic Patient-Reported Outcome (ePRO) Collection By an Outcome Registry, a CIBMTR Study of Patients on the Centers for Medicaid & Medicare Coverage with Evidence Development (CMS CED) Myelodysplasia Protocol

  2020cited by this paper
• A Phase 2 Study of F-652, a Novel Tissue-Targeted Recombinant Human Interleukin-22 (IL-22) Dimer, for Treatment of Newly Diagnosed Acute Gvhd of the Lower GI Tract

  2020cited by this paper
• Hematopoietic Cell Transplantation in Patients With Primary Immune Regulatory Disorders (PIRD): A Primary Immune Deficiency Treatment Consortium (PIDTC) Survey

  2020cited by this paper
• Priorities for Improving Outcomes for Non-Malignant Blood Diseases: A Report from the Blood and Marrow Transplant Clinical Trials Network.

  2020cited by this paper
• Multicenter evaluation of parametric response mapping as an indicator of bronchiolitis obliterans syndrome after hematopoietic stem cell transplantation

  2020cited by this paper
• Prospective study of a novel, radiation-free, reduced-intensity bone marrow transplantation platform for primary immunodeficiency diseases.

  2020cited by this paper
• Propranolol inhibits molecular risk markers in HCT recipients: a phase 2 randomized controlled biomarker trial.

  2020cited by this paper
• Bispecifics, trispecifics, and other novel immune treatments in myeloma.

  2020cited by this paper
• The evolution of NK cell immunotherapy for hematologic malignancies: A historical and contemporary perspective.

  2020cited by this paper
• Comparison of Haploidentical Bone Marrow versus Matched Unrelated Donor Peripheral Blood Stem Cell Transplantation with Posttransplant Cyclophosphamide in Patients with Acute Leukemia

  2020cited by this paper
• Dose-escalated interleukin-2 therapy for refractory chronic graft-versus-host disease in adults and children.

  2019cited by this paper
• Safety and Effectiveness of Vedolizumab in Patients with Steroid-Refractory Gastrointestinal Acute Graft-versus-Host Disease: A Retrospective Record Review.

  2019cited by this paper
• Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1-2 trial.

  2019cited by this paper
• Increasing Diversity in Clinical Trials: Overcoming Critical Barriers.

  2019cited by this paper
• Autologous Transplantation, Consolidation, and Maintenance Therapy in Multiple Myeloma: Results of the BMT CTN 0702 Trial.

  2019cited by this paper
• Burden and impact of multifactorial geriatric syndromes in allogeneic hematopoietic cell transplantation for older adults.

  2019cited by this paper
• Autologous transplantation as consolidation for high risk aggressive T-cell non-Hodgkin lymphoma: a SWOG 9704 intergroup trial subgroup analysis

  2019cited by this paper
• US Cancer Centers of Excellence Strategies for Increased Inclusion of Racial and Ethnic Minorities in Clinical Trials.

  2019cited by this paper
• Haploidentical donor transplants for severe aplastic anemia.

  2019cited by this paper
• Outcomes of Related and Unrelated Donor Searches Among Patients with Primary Immunodeficiency Diseases Referred for Allogeneic Hematopoietic Cell Transplantation.

  2019cited by this paper
• A Phase 3 Randomized Trial of Voxelotor in Sickle Cell Disease.

  2019cited by this paper
• External validation and comparison of multiple prognostic scores in allogeneic hematopoietic stem cell transplantation.

  2019cited by this paper
• Addition of sirolimus to standard cyclosporine plus mycophenolate mofetil-based graft-versus-host disease prophylaxis for patients after unrelated non-myeloablative haemopoietic stem cell transplantation: a multicentre, randomised, phase 3 trial.

  2019cited by this paper
• Cellular therapy: Adoptive immunotherapy with expanded natural killer cells

  2019cited by this paper
• Immunogenicity and safety of the adjuvanted recombinant zoster vaccine in adults with haematological malignancies: a phase 3, randomised, clinical trial and post-hoc efficacy analysis.

  2019cited by this paper
• Adaptive platform trials: definition, design, conduct and reporting considerations

  2019cited by this paper
• Polatuzumab Vedotin in Relapsed or Refractory Diffuse Large B-Cell Lymphoma

  2019cited by this paper
• More precisely defining risk peri-HCT in pediatric ALL: pre- vs post-MRD measures, serial positivity, and risk modeling.

  2019cited by this paper
• The rapidly changing landscape in mature T‐cell lymphoma (MTCL) biology and management

  2019cited by this paper
• Phase I Dose-Escalation Study of Venetoclax Plus BEAM Followed By Autologous Stem Cell Transplant (ASCT) for Chemoresistant or High-Risk Relapsed/Refractory Non-Hodgkin Lymphoma (NHL)

  2019cited by this paper
• Impact of Conditioning Intensity of Allogeneic Transplantation for Acute Myeloid Leukemia With Genomic Evidence of Residual Disease.

  2019cited by this paper
• Representation of Minorities and Women in Oncology Clinical Trials: Review of the Past 14 Years.

  2018cited by this paper
• Representation of Minorities and Elderly Patients in Multiple Myeloma Clinical Trials.

  2018cited by this paper
• Single Antigen-Mismatched Unrelated Hematopoietic Stem Cell Transplantation Using High-Dose Post-Transplantation Cyclophosphamide Is a Suitable Alternative for Patients Lacking HLA-Matched Donors.

  2018cited by this paper
• Prognostic factors influencing survival after allogeneic transplantation for AML/MDS patients with TP53 mutations.

  2018cited by this paper
• Outcomes of Measurable Residual Disease in Pediatric Acute Myeloid Leukemia before and after Hematopoietic Stem Cell Transplant: Validation of Difference from Normal Flow Cytometry with Chimerism Studies and Wilms Tumor 1 Gene Expression.

  2018cited by this paper
• A New Framework for Patient Engagement in Cancer Clinical Trials Cooperative Group Studies

  2018cited by this paper
• The importance of patient-reported outcomes in clinical trials and strategies for future optimization

  2018cited by this paper
• Abatacept for GVHD Prophylaxis after Hematopoietic Stem Cell Transplantation (HCT) for Pediatric Sickle Cell Disease (SCD): A Sickle Transplant Alliance for Research (STAR) Trial

  2018cited by this paper
• Clinical and Biological Correlates of Neurotoxicity Associated with CAR T-cell Therapy in Patients with B-cell Acute Lymphoblastic Leukemia.

  2018cited by this paper
• Phase I/II Study of Stem-Cell Transplantation Using a Single Cord Blood Unit Expanded Ex Vivo With Nicotinamide

  2018cited by this paper
• Haploidentical Donor Bone Marrow Transplantation for Severe Aplastic Anemia.

  2018cited by this paper
• A Phase 3 Trial of l‐Glutamine in Sickle Cell Disease

  2018cited by this paper
• De-Escalation and Discontinuation of Empirical Antibiotic Treatment in a Cohort of Allogeneic Hematopoietic Stem Cell Transplantation Recipients during the Pre-Engraftment Period.

  2018cited by this paper
• Early and late outcomes after cord blood transplantation for pediatric patients with inherited leukodystrophies.

  2018cited by this paper
• Molecular Minimal Residual Disease in Acute Myeloid Leukemia

  2018cited by this paper
• Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel.

  2017cited by this paper
• Master Protocols to Study Multiple Therapies, Multiple Diseases, or Both.

  2017cited by this paper
• Adaptive Clinical Trials: Advantages and Disadvantages of Various Adaptive Design Elements

  2017cited by this paper
• Prognostic Mutations in Myelodysplastic Syndrome after Stem‐Cell Transplantation

  2017cited by this paper
• Infectious complications of CD19-targeted chimeric antigen receptor-modified T-cell immunotherapy.

  2017cited by this paper
• Sickle cell disease: an international survey of results of HLA-identical sibling hematopoietic stem cell transplantation.

  2017cited by this paper
• Early recovery of T-cell function predicts improved survival after T-cell depleted allogeneic transplant

  2017cited by this paper
• Crizanlizumab for the Prevention of Pain Crises in Sickle Cell Disease

  2017cited by this paper
• Eltrombopag Added to Standard Immunosuppression for Aplastic Anemia

  2017cited by this paper
• Phase 1 clinical trial using mbIL21 ex vivo-expanded donor-derived NK cells after haploidentical transplantation.

  2017cited by this paper
• Microbiota Disruption Induced by Early Use of Broad-Spectrum Antibiotics Is an Independent Risk Factor of Outcome after Allogeneic Stem Cell Transplantation.

  2017cited by this paper
• An early-biomarker algorithm predicts lethal graft-versus-host disease and survival.

  2017cited by this paper
• National Institutes of Health Hematopoietic Cell Transplantation Late Effects Initiative: Developing Recommendations to Improve Survivorship and Long-Term Outcomes.

  2017cited by this paper
• Prospective study of nonmyeloablative, HLA-mismatched unrelated BMT with high-dose posttransplantation cyclophosphamide.

  2017cited by this paper
• TP53 and Decitabine in Acute Myeloid Leukemia and Myelodysplastic Syndromes.

  2016cited by this paper
• A trial of unrelated donor marrow transplantation for children with severe sickle cell disease.

  2016cited by this paper
• Prognostic Value of Ki-67 Index, Cytology, and Growth Pattern in Mantle-Cell Lymphoma: Results From Randomized Trials of the European Mantle Cell Lymphoma Network.

  2016cited by this paper
• Indications and Results of HLA-Identical Sibling Hematopoietic Cell Transplantation for Sickle Cell Disease.

  2016cited by this paper
• Cytokine-induced memory-like natural killer cells exhibit enhanced responses against myeloid leukemia

  2016cited by this paper
• Life after transplant: are we becoming high maintenance in AML?

  2016cited by this paper
• Cytomegalovirus viremia, disease, and impact on relapse in T-cell replete peripheral blood haploidentical hematopoietic cell transplantation with post-transplant cyclophosphamide

  2016cited by this paper
• Reduced-intensity transplantation for lymphomas using haploidentical related donors vs HLA-matched unrelated donors.

  2016cited by this paper
• Outcomes of Nonmyeloablative HLA-Haploidentical Blood or Marrow Transplantation With High-Dose Post-Transplantation Cyclophosphamide in Older Adults.

  2015cited by this paper
• Blood and marrow transplant clinical trials network state of the Science Symposium 2014.

  2015cited by this paper
• Long-term functional outcomes of children with hurler syndrome treated with unrelated umbilical cord blood transplantation.

  2015cited by this paper
• Effectiveness and safety of lower dose prednisone for initial treatment of acute graft-versus-host disease: a randomized controlled trial

  2015cited by this paper
• Low Socioeconomic Status, Adverse Gene Expression Profiles, and Clinical Outcomes in Hematopoietic Stem Cell Transplant Recipients

  2015cited by this paper
• Budesonide/Formoterol for bronchiolitis obliterans after hematopoietic stem cell transplantation.

  2015cited by this paper
• Predictive value of bronchiolitis obliterans syndrome stage 0p in chronic graft-versus-host disease of the lung.

  2015cited by this paper
• Ruxolitinib in corticosteroid-refractory graft-versus-host disease after allogeneic stem cell transplantation: a multicenter survey

  2015cited by this paper
• Prognostic value of FDG-PET prior to autologous stem cell transplantation for relapsed and refractory diffuse large B-cell lymphoma.

  2015cited by this paper
• Exercise and stress management training prior to hematopoietic cell transplantation: Blood and Marrow Transplant Clinical Trials Network (BMT CTN) 0902.

  2014cited by this paper
• Outcome of patients with abnl(17p) acute myeloid leukemia after allogeneic hematopoietic stem cell transplantation.

  2013cited by this paper

• Natural killer cells, macrophages and dendritic cells as innate immune therapies for blood cancers

  2026cites this paper
• Towards graf t-versus-host disease-free alternative donor transplant platforms for patients with acquired aplastic anemia

  2025cites this paper
• Up-front alternative donor HCT in severe aplastic anemia: gaps and opportunities to translate evidence into practice

  2025cites this paper
• Challenges and Opportunities in the Care of Hematopoietic Cell Transplant Survivors in the Modern Era.

  2025cites this paper
• Impact of Race and Ethnicity on Outcomes after Umbilical Cord Blood Transplantation.

  2024cites this paper
• How I treat post-immunotherapy relapsed B-ALL.

  2024cites this paper
• Expanding donor options: haploidentical transplant recipients are also highly likely to have a 7/8-matched unrelated donor

  2023cites this paper
• Short-course empiric antibiotics in children undergoing allogeneic hematopoietic cell transplant.

  2023cites this paper
• How do we improve the translation of new evidence into the practice of hematopoietic cell transplantation and cellular therapy?

  2023cites this paper
• Uniform conditioning regardless of donor in bone marrow transplantation for severe aplastic anemia

  2023cites this paper
• INSPIRED Symposium Part 2: Prevention and Management of Relapse Following CAR T-cell therapy for B-ALL.

  2023cites this paper
• Long-term Outcomes After Hematopoietic Cell Transplant in Peripheral T-Cell Lymphoma - The Oregon Health and Science University Experience.

  2023cites this paper
• If we do not count it, it does not count: ethnicity in allogeneic haemopoietic stem cell transplant in Australia

  2023cites this paper
• Haploidentical bone marrow transplantation in patients with relapsed or refractory severe aplastic anaemia in the USA (BMT CTN 1502): a multicentre, single-arm, phase 2 trial.

  2022cites this paper
• How We Use Risk Factors for Success or Failure of CD19 CAR T-cells to Guide Management of Children/AYA with B-cell ALL.

  2022cites this paper
• Combining PTCy and ATG for GvHD prophylaxis in non-malignant diseases.

  2022cites this paper
• Playing with fire: unrecognized AA genetic predisposition.

  2022cites this paper